Author details

Full Name

Elliott M Antman

Affiliation

ORCID

Career Start Year

1975

Papers

627

H Index

148

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36987929	Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation.	Eur J Heart Fail	2023
37949625	Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA.		2023
37211048	Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trial.	Int J Cardiol	2023
37019195	Evaluation of obstructive sleep apnea among consecutive patients with all patterns of atrial fibrillation using WatchPAT home sleep testing.		2023
37127146	Breathless nights and heart flutters: Understanding the relationship between obstructive sleep apnea and atrial fibrillation.		2023
37100536	Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes.		2023
35076699	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis.	JAMA Netw Open	2022
36017608	Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial.	Europace	2022
36198177	Atrial Fibrillation and Catheter Ablation.	N Engl J Med	2022
36260791	Atrial Fibrillation - What Is It and How Is It Treated?	N Engl J Med	2022
36812603	Privacy-aware multi-institutional time-to-event studies.	PLOS Digit Health	2022
34990581	Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups.	American Heart Journal	2022
35252395	Ideal Cardiovascular Health in Young Adults With Established Cardiovascular Diseases.	Front Cardiovasc Med	2022
34962979	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.	European Heart Journal - Cardiovascular Pharmacotherapy	2022
35165869	Sodium and Health: Old Myths and a Controversy Based on Denial.	Curr Nutr Rep	2022
35106506	The inclusion of augmented intelligence in medicine: A framework for successful implementation.	Cell Reports Medicine	2022
35076698	Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma.	JAMA Netw Open	2022
34810179	Exploring patient experiences coping with using multiple medications: a qualitative interview study.	BMJ Open	2021
33493453	Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study.	Am Heart J	2021
34290276	A precision medicine approach to sex-based differences in ideal cardiovascular health.	Sci Rep	2021
33801949	Data from Digital Health Devices Informs Ideal Cardiovascular Health.	J Pers Med	2021
33587659	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.	Circulation	2021
33587654	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials.	Circulation	2021
34167651	Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?	Journal of the American College of Cardiology	2021
33999548	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.	N Engl J Med	2021
33840208	Nonprofit Advocacy at the American Heart Association: Creating a Visionary Way Forward at Our 40th Anniversary: An American Heart Association Policy Statement.	Circulation	2021
33663737	Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.	Journal of the American College of Cardiology	2021
34205862	Ideal Cardiovascular Health in Former Smokers.	J Clin Med	2021
33558758	Comprehensive characterization of protein-protein interactions perturbed by disease mutations.	Nat Genet	2021
33446422	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.	J Clin Neurosci	2021
33760027	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.	Eur Heart J	2021
33599361	The path to universality.	European Journal of Heart Failure	2021
34353540	A Targeted Proteomic Approach Identifies Novel Biomarkers ofÂ Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48.	J Am Coll Cardiol	2021
32920808	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.	Thrombosis and Haemostasis	2021
33185476	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.	Circulation	2021
33115823	A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 Pandemic.	J Pharmacol Exp Ther	2021
33063112	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58Â 634 patients across four randomized controlled trials.	European Heart Journal - Cardiovascular Pharmacotherapy	2021
34649522	Digital health device measured sleep duration and ideal cardiovascular health: an observational study.	BMC Cardiovasc Disord	2021
34367681	An overview of the process, progress, and outcomes of a National Center for Accelerated Innovation: The Boston Biomedical Innovation Center Experience.	J Clin Transl Sci	2021
32717043	Pooling Data From Individual Clinical Trials in the COVID-19 Era.	JAMA - Journal of the American Medical Association	2020
32081368	Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor.	Am J Cardiol	2020
31687762	Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.	European Heart Journal - Cardiovascular Pharmacotherapy	2020
32008850	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial.	International Journal of Cardiology	2020
32227752	Managing Stable Ischemic Heart Disease.	New England Journal of Medicine	2020
32164882	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With AcuteÂ Coronary Syndrome.	J Am Coll Cardiol	2020
33148013	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.	Circ Cardiovasc Qual Outcomes	2020
32877597	Invasive or Conservative Strategy for Stable Coronary Disease. Reply.	New England Journal of Medicine	2020
32505370	Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups.	International Journal of Cardiology	2020
31296289	Edoxaban Versus Warfarin in PatientsÂ With Atrial Fibrillation and History of Liver Disease.	Journal of the American College of Cardiology	2019
31597460	Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.	Circulation	2019